Médecine

Paramédical

Autres domaines


S'abonner

Prognostic factors in Merkel cell carcinoma: Analysis of 240 cases - 09/02/13

Doi : 10.1016/j.jaad.2012.09.036 
Tina I. Tarantola, MD a, , Laura A. Vallow, MD d, Michele Y. Halyard, MD e, Roger H. Weenig, MD g, Karen E. Warschaw, MD f, Travis E. Grotz, MD b, James W. Jakub, MD b, Randall K. Roenigk, MD a, Jerry D. Brewer, MD a, Amy L. Weaver, MS c, Clark C. Otley, MD a
a Department of Dermatology, Mayo Clinic, Rochester, Minnesota 
b Department of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minnesota 
c Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota 
d Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida 
e Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona 
f Department of Dermatology, Mayo Clinic, Scottsdale, Arizona 
g Department of Dermatology, University of Minnesota, Minneapolis, Minnesota 

Reprint requests: Tina I. Tarantola, MD, Skin Cancer Center of NW Florida, 540 Fontaine St, Pensacola, FL 32503.

Abstract

Background

Knowledge regarding behavior of and prognostic factors for Merkel cell carcinoma (MCC) is limited.

Objective

We sought to further understand the characteristics, behavior, prognostic factors, and optimal treatment of MCC.

Methods

A multicenter, retrospective, consecutive study of patients with known primary MCC was completed. Overall survival and survival free of locoregional recurrence were calculated and statistical analysis of characteristics and outcomes was performed.

Results

Among the 240 patients, the mean age at diagnosis was 70.1 years, 168 (70.0%) were male, and the majority was Caucasian. The most common location was head and neck (111, 46.3%). Immunosuppressed patients had significantly worse survival, with an overall 3-year survival of 43.4% compared with 68.1% in immunocompetent patients. In our study, patients with stage II disease had improved overall survival versus those with stage I disease, in a statistically significant manner. Patients with stage III disease had significantly worse survival compared with stage I and with stage II. Primary tumor size did not predict nodal involvement.

Conclusion

The data presented represent one of the largest series of primary MCC in the literature and confirm that MCC of all sizes has metastatic potential, supporting sentinel lymph node biopsy for all primary MCC. Because of the unpredictable natural history of MCC, we recommend individualization of care based on the details of each patient’s tumor and clinical presentation.

Le texte complet de cet article est disponible en PDF.

Key words : Merkel cell carcinoma, neuroendocrine carcinoma, nonmelanoma skin cancer, primary neuroendocrine carcinoma of skin, prognosis, retrospective

Abbreviations used : AJCC, CI, ELND, HR, IQR, MCC, NCCN, SLNB, TLND, XRT


Plan


 Funding sources: None.
 Conflicts of interest: None declared.


© 2012  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 68 - N° 3

P. 425-432 - mars 2013 Retour au numéro
Article précédent Article précédent
  • Histopathology and correlates of systemic disease in adult Henoch-Schönlein purpura: A retrospective study of microscopic and clinical findings in 68 patients at Mayo Clinic
  • Timothy J. Poterucha, David A. Wetter, Lawrence E. Gibson, Michael J. Camilleri, Christine M. Lohse
| Article suivant Article suivant
  • Unknown primary Merkel cell carcinoma: 23 new cases and a review
  • Tina I. Tarantola, Laura A. Vallow, Michele Y. Halyard, Roger H. Weenig, Karen E. Warschaw, Amy L. Weaver, Randall K. Roenigk, Jerry D. Brewer, Clark C. Otley

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.